Request Demo

Last update 19 Feb 2025

Vorinostat

Last update 19 Feb 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Octanedioic acid hydroxyamide phenylamide, SAHA, SHH

+ [12]

Target

HDACs

Mechanism

HDAC inhibitors(Histone deacetylase inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [6]

Active Indication

Cutaneous T-Cell LymphomaAnus NeoplasmsPenile Neoplasms+ [9]

Inactive Indication

Acute Lymphoblastic LeukemiaAcute myeloid leukaemia with 11q23 abnormalityAcute Myeloid Leukemia+ [66]

Originator Organization

Merck & Co., Inc.

Active Organization

Unravel Biosciences, Inc.Startup

Merck Sharp & Dohme Corp.

Taiho Pharmaceutical Co., Ltd.

+ [2]

Inactive Organization

Sinopharm YiXin Pharmaceutical Co., Ltd.

Genentech, Inc.

Millennium Pharmaceuticals, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

US (06 Oct 2006),

Cutaneous T-Cell Lymphoma

RegulationOrphan Drug (US), Orphan Drug (JP)

Structure/Sequence

Molecular FormulaC14H20N2O3

InChIKeyWAEXFXRVDQXREF-UHFFFAOYSA-N

CAS Registry149647-78-9

279

Clinical Trials associated with Vorinostat

NCT05608369

/ Not yet recruitingPhase 2IIT

A Phase 2 Study of Vorinostat in Combination With Chemoradiation in Patients With Locally Advanced HPV Negative HNSCC

The purpose of this study is to learn more about a drug called Vorinostat (an experimental drug) in combination with chemoradiation. The intention of this study is to learn if this drug is safe for the participants and whether this drug with chemoradiation is able to further increase the clinical efficacy of chemoradiation, which is an approved therapy. The main question it aims to answer is: How may Vorinostat interact with standard chemotherapy and radiation therapy in head and neck cancer? Participants will receive the study drug (Vorinostat) as a pre-treatment, followed by standard chemoradiation.

Start Date01 Jun 2025

Sponsor / Collaborator

The Case Comprehensive Cancer Center

NCT04339751

/ RecruitingPhase 2IIT

The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease

Background:
Cushing s disease is caused by excess ACTH hormone release by a benign tumor of the pituitary gland. It can lead to decreased quality of life and early death. The current best treatment for Cushing s disease is surgery. If surgery does not work or if the tumor returns, there are no more good treatment options. Vorinostat, which is approved to treat a type of lymphoma, might be a treatment option.
Objective:
To test vorinostat to see if it can kill tumor cells and change the number of hormones released in people with Cushing s disease.
Eligibility:
People ages 18 and older who have Cushing s disease and are scheduled for surgery under protocol 03-N-0164 to remove a tumor in their pituitary gland
Design:
Participants will be screened under protocol 03-N-0164.
Participants will stay in the hospital for 8 days before their surgery.
On the first day, participants will have a physical exam and blood tests. They will have their urine collected for testing all day. They will have an ECG: For this, small metal disks or sticky electrode pads will be placed on their chest to record heart activity.
For the next 7 days, participants will have blood tests and all-day urine collection. They will drink at least 2 liters of fluid per day. They will take the study drug by mouth each morning.
On the eighth day, participants will have their surgery. Leftover tissue will be collected for research.
On the day they are discharged from the hospital, participants will have a physical exam and blood tests.

Start Date24 Feb 2025

Sponsor / Collaborator

National Institute of Neurological Disorders & Stroke

NCT06693284

/ RecruitingEarly Phase 1IIT

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

This is a single center Phase 0 "window of opportunity" trial for the treatment of newly diagnosed, PRC2 deficient, primary malignant peripheral nerve sheath tumors (MPNSTs) with a short course of the combination of mirdametinib and vorinostat prior to the most appropriate standard of care treatment for their specific tumor (typically localized radiation followed by surgical resection). Four to eight patients, 12 years of age or older and meeting the study's biomarker inclusion criteria, would be enrolled onto this trial. After voluntary written consent (assent with parent consent for minors) the patient undergoes MRI and PET imaging of the tumor and a needle biopsy to collect tumor is performed. Patients with histone H3K27 trimethylation deficient MPNST, as confirmed by immunohistochemistry, receive a single 28-day course of mirdametinib and vorinostat at standard oral dosing for each. At day 26, 27, or 28 the patient returns to clinic for a research visit repeating the baseline MRI and PET imaging and the needle biopsy for tumor tissue.
This ends direct study participation. The patient goes on to the most appropriate standard of care treatment for their MPNST. Information about the subsequent standard of care treatment is collected for the purposes of this study.

Start Date01 Dec 2024

Sponsor / Collaborator

University of Minnesota

100 Clinical Results associated with Vorinostat

100 Translational Medicine associated with Vorinostat

100 Patents (Medical) associated with Vorinostat

6,055

Literatures (Medical) associated with Vorinostat

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab

Article

Author: Kim, Youn H. ; Akilov, Oleg ; Scarisbrick, Julia ; Bagot, Martine ; Ristuccia, Robert ; Dwyer, Karen ; Wu, Wende ; Foss, Francine

PURPOSE:

Mogamulizumab demonstrated improved outcomes vs. vorinostat across a range of disease and patient characteristics in patients with mycosis fungoides or Sézary syndrome in the MAVORIC trial.

MATERIALS AND METHODS:

This post-hoc analysis further examined MAVORIC data to assess factors associated with long-term response (ORR >12 months), time to next treatment (TTNT), and impact of concomitant steroid use, lymphopenia, and mogamulizumab-associated rash (MAR) on patient response.

RESULTS:

A higher proportion of patients achieved ORR lasting ≥4, 6, 8, or 12 months in the mogamulizumab vs. vorinostat arm. Long-term response was also observed in mogamulizumab-treated patients with more advanced disease (stage IVA1 [17/20], B2 blood involvement [18/20], and SS [14/20]). PFS was significantly longer (9.4 vs. 3.1 months; p < 0.0001) in mogamulizumab vs. vorinostat-treated patients taking concomitant steroids. Mogamulizumab-treated patients experienced longer TTNT vs. vorinostat. Lymphopenia and MAR were associated with response to mogamulizumab.

CONCLUSIONS:

MAVORIC demonstrated greater efficacy with mogamulizumab vs. vorinostat in relapsed/refractory patients with CTCL, including those with more advanced disease. Concomitant steroid use improved ORR and PFS but did not impact vorinostat outcomes. Overall responses occurred more frequently in mogamulizumab-treated patients that developed lymphopenia than those that did not. A higher percentage of patients with MAR had an overall response than those without MAR.

01 Jun 2025·Case Studies in Chemical and Environmental Engineering

Untargeted metabolomic LC-HRMS combined with chemometric reveal metabolites change from sorghum flakes affected by food processing

Author: Anggraeni, Ayu Septi ; Suratno ; Noviana, Ika Mulawati Purwanti ; Utami, Indrawati Dian ; Nurfahmi, Laely ; Khasanah, Yuniar ; Alam, Lucky Prabowo Miftachul ; Windarsih, Anjar

A non-targeted UHPLC-HRMS metabolomics approach combined with chemometric anal. was employed to assess the change in metabolite profiles of sorghum flakes based on food processing techniques.The result showed that fatty acids were the most abundant metabolites, followed by lipids, amino acids, alkaloids, amines, and polyphenols, representing key metabolic markers influenced by food processing in sorghum flakes.Specific metabolites, including 15S-Hydroxyeicosatrienoic acid (15S-HETrE), terminaline, vitamin E acetate, furan fatty acid F6, all-trans-retinal, and fingolimod, exhibited increased concentrations during oven processing compared to raw sorghum, likely due to their thermal stability.This study provides valuable insights into effect of food processing effect on metabolites profiles.

01 May 2025·PHYTOCHEMISTRY

HDAC inhibitor SAHA triggers the production of previously undescribed sesquiterpenes and undergoes biotransformation by the fungus Robillarda sessilis from Verbena officinalis L.

Article

Author: Yang, Xiaolong ; Wang, Wenjing ; Liu, Qingpei ; Ran, Shan ; Huang, Junguo ; Liao, Liangxiu ; Zhu, Tao

Cultivation of the endophytic fungus Robillarda sessilis XL-308 with SAHA resulted in the discovery of two previously undescribed cyclonerane sesquiterpenes (1 and 2), one previously unreported norcadinane type sesquiterpene (3), and seven suberanilohydroxamic acid (SAHA) derivatives (4-10). The identification of previously undescribed compounds was confirmed through NMR spectroscopic analyses, quantum chemistry calculations, and single-crystal X-ray crystallography. Among them, compounds 1 and 2 were products of the silenced genome in XL-308 that activated by SAHA. Concurrently, SAHA underwent biotransformation because of its moderate toxicity towards this fungus. It was hypothesized that the hydroxamic acid group in SAHA triggering the self-defense mechanism of XL-308 and converting SAHA into a less toxic derivative 5.

News (Medical) associated with Vorinostat

30 Jan 2025

·www.businesswire.com

Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe

GALASHIELS & MARLOW, England & BAAR, Switzerland--( BUSINESS WIRE )--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd., and Swixx BioPharma AG today announced that the Croatian National Health Insurance Fund (NHIF) and the Bulgarian Ministry of Health have both approved the reimbursement of POTELIGEO ® (mogamulizumab) for adult patients with mycosis fungoides (MF), and Sézary syndrome (SS). MF and SS are two subtypes of cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin’s lymphoma that presents and persists in the skin and can cause debilitating physical, emotional and social challenges. 1 MF—the most common CTCL subtype—accounts for approximately 60% of all CTCLs. 2 With an average time to diagnosis of 3-4 years, MF is typically characterised by skin symptoms including patches or plaques, skin redness and tumours. 3,4 SS is much rarer, accounting for around 5% of CTCLs, 5 and is more aggressive, causing severe itching, erythroderma, intense scaling of the skin and frequent hair loss. 6 Jeremy Morgan, President of Kyowa Kirin International, commented: “ I am delighted that the Croatian and Bulgarian authorities have agreed to reimburse POTELIGEO for MF and SS patients. Both decisions are important milestones for people impacted by these rare and challenging forms of CTCL, and with mogamulizumab now reimbursed in more than 20 countries across the EMEA region we remain as committed as ever to delivering life changing value for people impacted by under-diagnosed and under-served diseases, and making more people smile.” Poteligeo is distributed in Central and Eastern Europe by Swixx, on behalf of KKI. The two companies signed a Promotion and Distribution Agreement in October 2022. Under the terms of the agreement, Swixx will exclusively market, promote and distribute mogamulizumab in both Croatia and Bulgaria, among other countries. “ At Swixx, our mission is to unlock access to innovative medicines, and the recent reimbursement approvals in Croatia and Bulgaria mark significant progress in improving therapeutic options for patients with MF and SS in those markets,” said Dezso Martha, Chief Operating Officer of Swixx. “ We will continue working closely with health authorities, the scientific community, and Kyowa Kirin to expand access to this important medicine, ensuring better outcomes for patients across our Central and Eastern European countries.” With Croatian reimbursement effective as of 15 th November 2024, and Bulgaria’s Ministry of Health confirming reimbursement as of 2 nd January 2025, both decisions build on the inclusion of POTELIGEO ® (mogamulizumab) in the Polish Ministry of Health’s Drug Programme announced in July 2024 and the ongoing expansion of access to patients across Central and Eastern Europe (CEE). About Poteligeo (mogamulizumab) Mogamulizumab is a first-in-class humanised monoclonal antibody directed against CC-chemokine receptor 4 (CCR4), a protein consistently expressed on cancerous cells seen in both MF and SS. 7-9 Once mogamulizumab binds to CCR4, it increases attraction of immune cells from the immune system to destroy the cancerous cells. 10 About MF and SS MF and SS are two subtypes of CTCL, which is itself a rare form of non-Hodgkin’s lymphoma that presents and persists in the skin. 1 CTCL is treatable, but is not generally considered to be curable, and there has been a clear unmet need for novel treatment options. As well as the obvious impact of symptoms upon patients, there can be significant erosions to quality of life for those caring for an individual living with CTCL. 11 MF and SS are characterised by localisation of cancerous white blood cells called T lymphocytes (T cells), to the skin. 12 These cancerous T cells consistently express a protein called CCR4, which enables them to move from the blood to the skin. 7-9 When these cancerous T cells move to the skin, this results in the visible early skin symptoms of red patches or plaques which can resemble psoriasis or eczema in the early stages of the disease. 6 Later, for some patients, skin involvement may evolve to include tumours or reddening of the majority of the skin’s surface (erythroderma). MF—the most common CTCL subtype—accounts for approximately 60% of all CTCLs 2 and is typically indolent, characterised by skin symptoms including patches or plaques, skin redness and tumours. 3,4 SS is much rarer, accounting for around 5% of CTCLs, 5 and is more aggressive, 6 with high levels of blood involvement. 5 It can cause severe itching, erythroderma, intense scaling of the skin and frequent hair loss. 6 CTCL can take, on average, between 2 and 7 years for individuals to receive a confirmed diagnosis. 6 About Kyowa Kirin Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by severe and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across our four regions – Japan, Asia Pacific, North America, and EMEA/International. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com About Swixx BioPharma AG Swixx BioPharma is one of the fastest-growing, largest, intercontinental commercial platforms for the biopharmaceutical industry. Swixx operates subsidiaries across Central and Eastern Europe, Greece, Russia, several Eurasian countries, the Middle East, and via Biopas, a Swixx BioPharma company, in almost 20 Latin American countries. Swixx BioPharma Group has over 1,600 employees and sales likely to exceed a billion Euros in 2024. The company has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof. For more information about Swixx BioPharma, please visit: www.swixxbiopharma.com References 1 Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192-1204. 2 Willemze R, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714. 3 Scarisbrick, J, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2019;181(20):350–357. 4 Demierre M-F, et al. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life. Cancer. 2006;107(10):2504-2511. 5 Trautinger F, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. European Journal of Cancer. 2017;77:57–74. 6 Lymphoma Coalition. Cutaneous lymphoma – a patient’s guide. Available at: https://lymphomacoalition.org/wpcontent/uploads/Cutaneous_lymphoma_-_patients_guide_-.pdf . Last accessed: January 2025. 7 Ferenczi K, et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119:1405–10. 8 Yoshie O, et al. Frequent Expression of CCR4 in Adult T-Cell Leukemia and Human T-cell Leukemia Virus Type 1-transformed T cells. Blood. 2002;99(5):1505–11. 9 Ishida T, et al. Clinical Significance of CCR4 Expression in Adult T-cell Leukemia/Lymphoma: Its Close Association With Skin Involvement and Unfavorable Outcome. Clin Cancer Res. 2003;9:3625–34. 10 Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171–174. 11 Williams et al (2020) – Health state utilities associated with caring for an individual with CTCL. Journal of Medical Economics. 2020; 23(10):1142-1150. 12 Scarisbrick JJ, Prince M, Vermeer MH, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol. 2015;33(32):3766-3773.

Phase 3Drug ApprovalLicense out/in

24 Oct 2024

·www.prnewswire.com

Unravel Biosciences and PECET Announce Collaboration to Conduct Clinical Trials of RVL-001 in Rett Syndrome and Pitt Hopkins Syndrome in Colombia

Study site selection and finalization of clinical trial agreement final step toward initiation of RVL-001 proof-of-concept clinical studies early next year BOSTON, Oct. 24, 2024 /PRNewswire/ -- Unravel Biosciences, Inc., ("Unravel"), an AI-enabled therapeutics company established to advance drugs for complex diseases, and the clinical research unit of the PECET of the University of Antioquia, certified in Good Clinical Practices by the Colombian Health Regulatory Authority ("INVIMA") and located in in Medellín, Colombia, today announced the finalization of a clinical trial agreement enabling PECET to be the designated study site for Unravel's RVL-001 proof of concept clinical trials for Rett syndrome (RTT) and Pitt Hopkins syndrome (PTHS). Unravel's proprietary BioNAV™ drug discovery platform identified RVL-001 as a potentially promising therapeutic drug for Rett Syndrome and PTHS. Building on previously announced initiatives by Unravel to initiate a proof-of-concept clinical trials of RVL-001 in Colombia for RTT as well as a collaboration by the Pitt Hopkins Research Foundation (PTHF) to conduct an extension study of RVL-001 in PTHS, today's agreement with PECET in Colombia formally establishes the clinical infrastructure for Unravel to rapidly evaluate BioNAV™ identified drugs in patients. "We are excited to collaborate with the highly skilled PECET team to accelerate therapeutics development for rare disease patients," said Richard Novak, Ph.D., Unravel Co-Founder and CEO. "By conducting multiple clinical trials in parallel at a single clinical trial site enables faster and less costly drug development to support more patients with unmet needs." RTT and PTHS are both rare neurogenetic disorders starting in early childhood that lead to debilitating cognitive, motor and autonomic disability. Despite one approved treatment for RTT, there remains a significant unmet need for novel treatments having meaningful efficacy and acceptable safety and tolerability. There are no known treatments for PTHS. In addition to Unravel's RVL-001 program for RTT and PTHS, the company has also initiated development work on RVL-002, a first-in-class novel molecule for Rett syndrome. Initiation of patient dosing for the RVL-001 trial in RTT and extension trial in PTHS are both anticipated in early 2025, with study startup activities including clinical trial material manufacturing and patient recruitment initiated earlier this year as previously announced. "We are pleased to be the designated clinical trial center for Unravel, it is a great challenge that we will take on with great enthusiasm to contribute to the search for solutions for this type of disease," said Iván Darío Vélez, Professor Emeritus of the University of Antioquia and founder of PECET. "PECET has extensive expertise conducting clinical studies with international biopharma sponsors including US to support worldwide registration and approval and we look forward to supporting Unravel in their development efforts". About Unravel Biosciences Unravel Biosciences revolutionizes drug development, uncovering disease-modifying targets from patient data powered by AI systems biology computation, rapid in vivo screening, and clinical validation of discovered targets with unprecedented efficiency. Unravel leverages its proprietary BioNAV™ foundational model of human health combining target and drug discovery, preclinical screening and patient stratification to find treatments for complex diseases. Unravel's platform has led to four clinical programs. Unravel's platform developed RVL001, a novel formulation to treat neurodevelopmental disorders, RVL002, a first-in-class new small molecule targeting mitochondrial metabolism, and RVL027, a molecule targeting a novel mechanism to treat dystonias. The rareSHIFT™ program provides platform access to foundation and biotech partners to accelerate and clinically derisk therapeutics using existing drugs as a key stepping stone to validating novel targets and mechanisms in real patient populations. and SOURCE Unravel Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Study

30 Sep 2024

·www.fiercebiotech.com

Cereno's HDAC inhibitor reduces risks from pulmonary arterial hypertension in phase 2 trial

Two-thirds of patients saw a sustained reduction in their pulmonary arterial pressure. Cereno Scientific’s hypertension drug was shown to improve the risk score of 43% of patients in a phase 2 study.Of the 21 participants with pulmonary arterial hypertension (PAH), nine demonstrated an improved risk score—a measurement of the risk of death from the condition—after 12 weeks of treatment with Cereno’s histone deacetylase (HDAC) inhibitor, dubbed CS1.A further six patients reported a stable risk score, meaning 71% of patients saw their score either improve or hold steady, the Swedish biotech noted in a post-market release Friday.Two-thirds of patients saw a sustained reduction in their pulmonary arterial pressure, while a third reported an improved functional class, a term for symptoms and physical capacity.Cereno’s shares were trading up 25% on the Stockholm stock exchange at 8.72 Swedish krona on Monday afternoon local time compared to a Friday closing price of 7 krona.The trial was also a success on its primary endpoint of proving the safety and tolerability of CS1, with no treatment-related serious adverse events. No changes in liver lab values or clinically significant drug-related bleedings or decreases in platelet counts were recorded, Cereno said. The company is now looking at moving CS1 into a pivotal trial and said it will use Friday’s “encouraging results” as the basis for opening talks with regulators.“We are excited to take the next steps in our journey to make a meaningful impact for patients with PAH,” Cereno’s Head of R&D Rahul Agrawal said in the release.“The CS1-003 trial demonstrated compelling signs of clinical efficacy already over a 12-week treatment period and we expect to see additional positive impact of CS1 with longer use of our drug in patients with PAH,” Agrawal added.HDACs help regulate gene expression. The FDA has already improved four HDAC inhibitors to treat blood cancers, including Merck & Co.’s Zolinza. Cereno is hoping CS1 will have success against PAH by “targeting the root cause of the disease, aiming to reverse the pathological vascular remodeling of the small lung arteries.”PAH is a rare, rapidly progressing disease in which the blood vessels narrow in the lungs, increasing blood pressure and leading to heart failure. Johnson & Johnson dominates the PAH market with its prostacyclin receptor agonist Uptravi and the endothelin receptor agonist Opsumit.In March, Merck & Co. muscled in on the action with the approval of the activin signaling inhibitor Winrevair, which the pharma has touted as acting directly on the underlying problem that causes the disease.Despite the increasingly crowded space, Cereno claimed in its release that “existing treatment alternatives are insufficient and do not address the root cause of the disease.”

Clinical ResultPhase 2

100 Deals associated with Vorinostat

External Link

KEGG	Wiki	ATC	Drug Bank
D06320	Vorinostat	L01XX38	DB02546

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cutaneous T-Cell Lymphoma	US	Merck Sharp & Dohme Corp.	06 Oct 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory Multiple Myeloma	Phase 3	-	Merck Sharp & Dohme Corp.	01 Dec 2008
Non-squamous non-small cell lung cancer	Phase 3	-	Merck Sharp & Dohme Corp.	01 May 2007
Malignant Pleural Mesothelioma	Phase 3	-	Merck Sharp & Dohme Corp.	30 Jun 2005
Estrogen receptor positive breast cancer	Phase 2	US	Merck Sharp & Dohme Corp.	11 Mar 2021
Metastatic breast cancer	Phase 2	US	Merck Sharp & Dohme Corp.	11 Mar 2021
Anus Neoplasms	Phase 2	FR	Merck Sharp & Dohme Corp.	28 Oct 2020
Penile Neoplasms	Phase 2	FR	Merck Sharp & Dohme Corp.	28 Oct 2020
Squamous cell carcinoma of head and neck metastatic	Phase 2	FR	Merck Sharp & Dohme Corp.	28 Oct 2020
Squamous cell carcinoma, metastatic	Phase 2	FR	Merck Sharp & Dohme Corp.	28 Oct 2020
squamous cell lung carcinoma	Phase 2	FR	Merck Sharp & Dohme Corp.	28 Oct 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02619253 (CTgov)	Phase 1	Advanced Urothelial Carcinoma \| Renal Cell Carcinoma \| Bladder Cancer	52	pembrolizumab+vorinostat (Expansion Cohort A)	ahrsctndoa(ssezduamjm) = emsalubphq qzdhsvitdl (fyfvoeybpm, cgiihxavuf - ttdjiwnpft) View more	-	18 Nov 2024
				pembrolizumab+vorinostat (Expansion Cohort B)	ahrsctndoa(ssezduamjm) = zmxuulrwdp qzdhsvitdl (fyfvoeybpm, xylpxaggch - bcqcjiylsj) View more
NCT04357873 (PEVOsq, AACR2024) Manual	Phase 2	Squamous Cell Carcinoma PD-L1 expression \| tumor-infiltrating lymphocytes quantification \| HPV typing ... View more	112	Pembrolizumab anVorinostatVorinostat combination	-	Positive	22 Mar 2024
				Pembrolizumab + Vorinostat (HPV+)	qzothghrhx(qwxmcrvkeh) = ezlehdinak jawlqmwrpn (jragjtsxvw )
NCT03198559 (CTgov)	Phase 1/2	HIV Infections	5	Vorinostat, NDC 00006-0568-40+Disulfiram, (National Drug Code) NDC 0378-4141-01	lthidzjlmd(gjpibmmhoz) = nieznptsdv ccphbjmqwa (qfbnkrnize, fiswpotlna - wfnbdqaojt) View more	-	09 Feb 2024
NCT02316340 (CTgov)	Phase 2	Metastatic Colorectal Carcinoma	42	Vorinostat+Hydroxychloroquine (Study Arm - VOR With HCQ)	tobacvssml(fzzhptsvlc) = vyllggnuwi qikrhsqsqa (xmpmyiiwti, kevldekqwc - rsrnzsakrj) View more	-	05 Jan 2024
				Regorafenib (Control Arm - Regorafenib)	tobacvssml(fzzhptsvlc) = ekglptixjo qikrhsqsqa (xmpmyiiwti, qhymdkxpek - kltocsygcz) View more
NCT01802333 (S1203, Pubmed \| Leukemia) Manual	Phase 3	Acute Myeloid Leukemia NPM1 \| FLT3	738	Daunorubicin and cytarabine (DA)	pdbxphhcsi(ulqfmfzgzp) = hqpxtggezx dzsfnukgik (rlsraxnkvd ) View more	Negative	01 Jan 2024
				Idarubicin with higher dose cytarabine (IA)	pdbxphhcsi(ulqfmfzgzp) = zsakbmcsgy dzsfnukgik (rlsraxnkvd ) View more
NCT04357873 (PEVOsq, ESMO 12023 \| ESMO 22023) Manual	Phase 2	Squamous Cell Carcinoma of Head and Neck	27	Pembrolizumab + Vorinostat	ykpqqmedgf(vvnlulpwyf) = iavbspnxul smwpyfetnf (klxtuizlqt, 6.6 - 39.4) View more	Positive	22 Oct 2023
EUCTR2019-003839-33-FR \| NCT04357873 (PEVOsq, ESMO 12023 \| ESMO 22023) Manual	Phase 2	squamous cell carcinoma of the anus p16	29	Pembrolizumab + Vorinostat	aymcvzfpgl(hzvvldesha) = kxozxhkzvb qmybksphyo (cpecbawcjz, 17.2 - 47.9) View more	Positive	22 Oct 2023
EUCTR2019-003839-33-FR \| NCT04357873 (PEVOsq, ESMO 12023 \| ESMO 22023) Manual	Phase 2	Squamous cell carcinoma of vulva	17	Pembrolizumab + Vorinostat	dmsnsdbyci(incaoecdux) = swwyglmqvt upktfqbwms (dihnizzvhr ) View more	Positive	22 Oct 2023
EUCTR2019-003839-33-FR \| NCT04357873 (PEVOsq, ESMO 12023 \| ESMO 22023) Manual	Phase 2	Cervical Squamous Cell Carcinoma	25	Pembrolizumab + Vorinostat	qfyyzopjjw(mrjevwcvlu) = yxilgrabje cxaxpypiuc (bvszuitlfh, 19.7 - 61.5) View more	Positive	22 Oct 2023
NCT04190056 (CTgov)	Phase 2	Metastatic breast cancer \| Estrogen receptor positive breast cancer	1	Vorinostat+Tamoxifen+pembrolizumab (Arm A (Pembrolizumab, Vorinostat, Tamoxifen))	pyskjjqtkv(icgikufqia) = ietsijagwg ihigdryjxx (sejcfiehku, obeqjvfcpo - bqnhvfbxuh) View more	-	31 Aug 2023
				Tamoxifen+pembrolizumab (Arm B (Pembrolizumab, Tamoxifen))	dyjmdxjtvm(mcundkcaqk) = umdowlrhut gxpzumwcpj (zrmimnavyg, anqwgghxyh - zxoswvfzcz) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis